

September 22, 2011



Lixte Biotechnology Holdings Announces Issuance of U.S. Patent for Lead Anti-Cancer Compound

EAST SETAUKET, N.Y., Sept. 22, 2011 /PRNewswire/ -- [John S. Kovach](#), M.D., Chair, Board of Directors and CEO of [Lixte Biotechnology Holdings, Inc.](#) (LIXT.PK), announces that the United States Patent and Trademark Office awarded a patent on its lead compound, LB-100, as well as a number of structurally related compounds, which has shown promising anti-cancer activity. Patent applications on these compounds are pending world wide. Lixte is presently completing pre-clinical studies of LB-100 in preparation for submitting an application to the Food and Drug Administration to conduct Phase I trials.

John Kovach, MD, founder and president of Lixte said, "We are extremely pleased that that LB-100 and several structurally related compounds have been recognized as novel potential anti-cancer compounds. LB-100 is an anti-cancer compound, which appears to prevent cancer cells from defending themselves against standard types of cancer treatments. In pre-clinical animal model systems, LB-100 enhances the killing of cancer cells by several widely used anti-cancer drugs as well as radiation treatments. If the improved anti-cancer activity of LB-100 combined with conventional anti-cancer treatments seen in animals is borne out against human cancers without undue toxicity, we hope that LB-100 may be associated with meaningful benefit to patients with several types of cancer."

About Lixte Biotechnology Holdings, Inc.

Lixte is a biotechnology company engaged in development of improved treatments for cancer and methods for detecting cancer. Lixte was created to capitalize on opportunities to develop low cost, specific and sensitive tests for the early detection of cancers. Over the past six years, however, the Company has evolved into what is now primarily a cancer drug discovery company, using biomarker technology to develop new potentially more effective anti-cancer drugs.

The Company is developing new treatments for several cancers for which better treatments are urgently needed. The primary focus is on the most common and most aggressive type of brain cancer of adults, glioblastoma multiforme ("GBM"). The research on brain tumors is being conducted with the National Institute of Neurological Disorders and Stroke ("NINDS") of the National Institutes of Health ("NIH") under a Cooperative Research and Development Agreement ("CRADA").

The Company expanded the scope of its program to other cancers of neural tissue (nerve and brain), including medulloblastoma, the most common brain tumor of children, and neuroblastoma, the most common cancer of children, and to other cancers of adults including sarcomas, melanomas, and breast cancer

Forward-Looking Statements

This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," "anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the condensed consolidated financial statements and notes thereto in the Quarterly Report on Form 10-QSB for the quarter ending July 31, 2011.

For additional information, please see:

www.Lixte.com

Investor Relations

Jeff Ramson

jramson@proactivecrg.com

Pro-Active Capital Resources Group

SOURCE Lixte Biotechnology Holdings, Inc.